Nanopore sequencing offers advantages in all areas of research. Our offering includes DNA sequencing, as well as RNA and gene expression analysis and future technology for analysing proteins.

Learn about applications
View all Applications
Resources Investors Careers News About Store Community Contact

Oxford Nanopore announces £48.4M ($59.2M) in new capital to support ongoing innovation and the rapid worldwide growth of nanopore sequencing

Tue 26th May 2020

26th May 2020, Oxford, UK:  Oxford Nanopore Technologies has raised £48.4M ($59.2M) in new capital.

The funding comes from new investors and existing shareholders in EMEA, US and Asia, and adds to the £29M of new capital raised in Q4 2019.  

Further information on Oxford Nanopore’s fundraising will be made available after full closing.

Oxford Nanopore’s sequencing devices are used in worldwide scientific research, and increasingly in regulated environments such as healthcare and food safety. The technology is being used extensively for epidemiology and research purposes in the current COVID-19 pandemic and the Company has a new category of COVID test, LamPORE, in advanced development.  London Calling, the Company’s annual conference, will be held online on 18-19 June; register here to attend. 

Open a chat to talk to our sales team